Hims & Hers Health, Inc. (HIMS) vs Neurocrine Biosciences, Inc. (NBIX)
- Hims & Hers Health, Inc. HIMS 28.07 −4.46%
- Neurocrine Biosciences, Inc. NBIX 135.71 −0.91%
Hims & Hers Health, Inc. and Neurocrine Biosciences, Inc. are both Drug Manufacturers Specialty & Generic companies. Neurocrine Biosciences, Inc. is the larger, with a market value of $13.9B against $6.9B — 2.0× the size. Hims & Hers Health, Inc. has negative trailing earnings, so its P/E is not meaningful; Neurocrine Biosciences, Inc. trades at 19.2×. Neurocrine Biosciences, Inc. grew revenue faster over the last twelve months: 34.4% against 28.0%. Neurocrine Biosciences, Inc. has the higher net margin (20.9% vs −5.51%) and the higher return on invested capital (15.0% vs −11.4%). Across the 20 metrics below, Neurocrine Biosciences, Inc. leads on 17 and Hims & Hers Health, Inc. on 3.
Valuation
Profitability
| Metric | HIMS | NBIX | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | 68.43% | 97.94% | 53.94% |
| Operating margin | (5.99%) | 23.56% | 0.00% |
| Net margin | (5.51%) | 20.91% | 0.00% |
| Free cash flow margin | 3.22% | 25.80% | 0.00% |
| Return on equity | (32.03%) | 22.09% | (0.40%) |
| Return on assets | (5.16%) | 15.26% | (3.32%) |
| Return on invested capital | (11.38%) | 15.04% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack